The Biden administration previously put forward a rule aimed at reinterpreting a statute that prevented the federal government from covering drugs “when used for weight loss,” as opposed to treating diabetes.
But the Trump administration believes finalizing such a proposal “is not appropriate at this time.”
“CMS may consider future policy options for AOMs pending further review of both the potential benefits of these drugs including updated clinical indications, and relevant costs including fiscal impacts on stakeholders such as state Medicaid agencies,” Catherine Howden, a spokeswoman, told CBS News.
Trending: Why Do 10 Nurses at the Same Hospital Have Brain Tumors?
Had the Trump administration let the proposal go forward, it could’ve cost them billions as weight-loss drugs are expensive. Drugs like Wegovy and Zepbound both cost roughly $1,000 before insurance. A congressional analysis pegged the exact
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!